Takeda wins auction for Nycomed

Takeda agrees to pay $14 billion for Swiss drug company Nycomed in Japan's largest-ever pharma M&A deal.

Takeda Pharmaceutical is set to buy Nycomed for 9.6 billion $13.7 billion in cash, in Japan’s second-largest outbound MA deal and its largest healthcare MA deal.

Takeda is already Japan’s largest pharmaceutical company and the acquisition will consolidate its position by some margin. But, equally, the deal will add to Takeda’s drug pipeline and its geographical reach.

Nycomed is well established in Europe and some high-growth emerging markets, with the...

To continue reading, please login or register for free

Click for more on: takeda | nycomed | pharmaceutical | drugs

Print Edition

FinanceAsia Print Edition